Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting
| Citation | 85 FR 71660 |
| Record Number | 2020-24870 |
| Published date | 10 November 2020 |
| Section | Notices |
| Court | National Institutes Of Health |
71660
Federal Register / Vol. 85, No. 218 / Tuesday, November 10, 2020 / Notices
New Animal Drugs for Minor Uses and
for Minor Species.’’ Received comments
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
•Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-2015-
09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT
:
Margaret Oeller, Center for Veterinary
Medicine (HFV–50), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–402–0566,
margaret.oeller@fda.hhs.gov.
SUPPLEMENTARY INFORMATION
: In the
Federal Register of July 15, 2020, FDA
published a notice announcing the
availability of draft GFI #61 entitled
‘‘Special Considerations, Incentives, and
Programs to Support the Approval of
New Animal Drugs for Minor Uses and
for Minor Species’’ with a 120-day
comment period.
Interested persons were originally
given until November 12, 2020, to
comment on the draft guidance. The
Agency received a request to allow
interested persons additional time to
comment. The request conveyed
concern that the initial 120-day
comment period did not allow sufficient
time to develop a comprehensive
response. FDA believes that an
extension of 60 days allows adequate
time for interested persons to submit
comments.
Dated: November 5, 2020.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2020–24970 Filed 11–9–20; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, NICHD.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended for the review, discussion,
and evaluation of individual intramural
programs and projects conducted by the
EUNICE KENNEDY SHRIVER
NATIONAL INSTITUTE OF CHILD
HEALTH & HUMAN DEVELOPMENT,
including consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, NICHD.
Date: December 4, 2020.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: A report by the Acting Scientific
Director, NICHD, on the status of the NICHD
Division of Intramural Research; current
organizational structure; to review and
evaluate personnel qualifications and
performance, and competence of individual
investigators.
Place: National Institutes of Health, 31
Center Drive, Bethesda, MD 20892 (Video-
Assisted Meeting).
Contact Person: Mary C. Dasso, Ph.D.,
Acting Scientific Director, Eunice Kennedy
Shriver National Institute of Child Health and
Human Development, NIH, 9000 Rockville
Pike, Building 31A, Room 2A46, Bethesda,
MD 20892, (301) 594–5984, dassom@
mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
www.nichd.nih.gov/about/meetings/Pages/
index.aspx, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.865, Research for Mothers
and Children, National Institutes of Health,
HHS)
Dated: November 4, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24870 Filed 11–9–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Emergency Awards: Rapid
Investigation of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS–CoV–2) and
Coronavirus Disease 2019 (COVID–19).
Date: December 18, 2020.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G53,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Konrad J. Krzewski, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G53, Rockville, MD
VerDate Sep<11>2014 17:21 Nov 09, 2020 Jkt 253001 PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\10NON1.SGM 10NON1
jbell on DSKJLSW7X2PROD with NOTICES
